Dedico el presente trabajo: A mi Madre, porque la amo y me lo dio todo, a mi Padre y Hermanos, por siempre estar, a la familia a los amigos a los

Texto completo

(1)

(2)

(3)

(4)

(5)

(6)

(7) .

(8)

(9) . . ! " #$$%& $ &'( ) " * !$' ) $ ' $ + $ $ & "&$ ,,-./000.

(10) . .

(11)

(12) 1

(13) 2

(14) 2

(15) 1

(16) 3

(17)

(18) !

(19)

(20) . 4 5 /00-.

(21)

(22) AA. .. A. 0. 2 6 A. C. 2 17

(23) A. M. 2

(24) A A. ... 6 A. .G. A A. /0. 881

(25) 7

(26) A. /C. 292 42 48 A A. /G.

(27)

(28) Dedico el presente trabajo: A mi Madre, porque la amo y me lo dio todo, a mi Padre y Hermanos, por siempre estar, a la familia… a los amigos…a los pacientes… a la honestidad y corrección en nuestros actos diarios… y a mi Sueño, para que un día se convierta en mi más preciada realidad.. "#$ %&'(' ) * +,' '- ". ..

(29) ! " #$$%& $ &'( ) " * !$' ) $ ' $ + $ $ & "&$ ,,-./000. /. "#$ %&'(' ) * +,' '- ".

(30) . Leucemia Mieloide Crónica (LMC), la más frecuente de las enfermedades mieloproliferativas, es una de las leucemias más estudiadas. Debido a la diversidad de formas de presentación y de tratamientos disponibles recibidos por los pacientes y a cómo estos influyen en la evolución de la enfermedad, decidimos realizar este estudio descriptivo analítico a fin de conocer la sobrevida total de los pacientes según hallazgos al diagnóstico y luego del tipo de tratamiento instaurado. Se encontraron 61 pacientes cuyos datos estaban disponibles en las historias clínicas encontradas. Se encontró una clara predisposición de la enfermedad hacia el sexo masculino. Los pacientes con fase acelerada o crisis blástica al diagnóstico tuvieron una menor sobrevida total con respecto a los pacientes con fase crónica al diagnóstico. Una mayor sobrevida también se observó en los pacientes con Score Sokal bajo e intermedio al diagnóstico y en los pacientes que utilizaron como tratamiento al interferón alfa. Palabras Claves: Leucemia Mieloide Crónica, Score Sokal, Interferon-Alfa, Respuesta Hematológica, Respuesta Citogenética. "#$ %&'(' ) * +,' '- ". 0.

(31) ! " #$$%& $ &'( ) " * !$' ) $ ' $ + $ $ & "&$ ,,-./000. 1. "#$ %&'(' ) * +,' '- ".

(32) 2 6. 2 6 +$(

(33) (( 2-(+ 3

(34) 4 ' ( ' -5$' $((5(6' +2-(+' % $&(7- $8' '( 3.4! 9($- ' ' +'' &#- - -'++(2- +$'2$(+ ++'(+ +-+( +$ $'$ ,(,(! ' ,:# , $(( (#-'(+ % '

(35) +- ;+( ' ' -5$' $((5(6' 3/4! -< +' ;+ ' '+-+(= (#-2'(+ $- (-6-+(2-= - +$ ' 6-+' 7(+' +(-'= ,- $- ->$ +(-' < #:- '&6( # : % (& -5$ 304! 5' +2-(+ 6+(- $8' &(- +- - 5-( &-(#-! ' ' (-6(& -'5$+(2- ('(' ?8'(+ #= < -5$ ' +8+ $(#- % @'(5(+ '5: +-- ' '#(' 7(+' (--6(6' % 5(+(-'! (-+( -5< < +( '&6( # : (& -5$ ' '-

(36) 7 2' 3

(37) 4 #7-(+= += &( ' ($( (++(2 +(-' $8' @26-' +- -- +$(&= &&$- A+B '2 .CD ' ' +(-' +- -5$ 314! E($(( +-6-+(- +- %;% ?'5- # +- ,$2#(+ - $(5(+- +' -$ -5$! ' ' (-++(2-=

(38) #7-(+ , '(&(( - +

(39) ! +' '- ' +(-' #(&' ' $(-! $(- +- -52- '2 +$&(-+(2- +- (&(- -# '&6(! 6' &@(6' $(- ' "#$ %&'(' ) * +,' '- ". C.

(40) ! " #$$%& $ &'( ) " * !$' ) $ ' $ + $ $ & "&$ ,,-./000. '8- (-(5(+- 67' $@' 5(-(+(-' ' 6-' $+' -6' - (-(+(+(2- % #'(2-

(41) 3C4!. &( <

(42) 5 ($ +' -8'(+ - ' '+( +- - -$( #-7(+ <((= ' , $ $+ +$( $@ '( 3F4! - 6(' ' - -5$ $% &(- '(= % - 6(' < +(' ,:#' (#-2'(+ ' +$ ( $(- (-' (-5% - 6+(2 ' +(-' +- ' -5$= +(($' ,+ - '( '& ' +(-' (#-'(+' ' .GG0 ,' H /III -

(43) !. F. "#$ %&'(' ) * +,' '- ".

(44) 2 17

(45). 2 17

(46) - ' '+((6*-(+= '+(6= - ;($-! - ($ # ' &'+- ' -$&' % ->$' ,('(' +-(+' ' ' +(-' (#-'(+' +- +$(

(47) (( 2-(+ ' H .GG0 ,' /III! ' 5 -+'( &'+ - ' -' +,(6 < ' -+-- - - (' '((:+(2- +$ - -'( $# -(+

(48) ! # ' &'+- ' ,('(' +-(+' +'-(-' - 6(+( +,(6' ('(' -(+'! '- +$

(49) '( J. ' ' +(-' $%' .K H' (#-'(+' +-

(50) -

(51) < +-- +- ' 6(&' <(' '( - .GG0*/III!. J. ' ' +(-' $%' .K H' (#-'(+' +-

(52) - ' ,'(' < +-- +- ' 6(&' <('= -' ' 5('

(53) - .GG0*/III! L +$ . J. +(-' +- (#-2'(+

(54) -

(55) - ' ,'('= < - +-+- ' 6(&' <(' - .GG0*/III!. J. +(-' $-' .K H'!. J. +(-' +-

(56) +- -+- -'( ('(- 7' % < ,% +(&( "#$ %&'(' ) * +,' '- ". M.

(57) ! " #$$%& $ &'( ) " * !$' ) $ ' $ + $ $ & "&$ ,,-./000. +<( ( <($(( ('(- $(-

(58) ! ' 6(&' <(' 5- ' '(#(-' J. 5$-(- $'+(-!. J. ;' - H'!. J.

(59)

(60)

(61)

(62)

(63) ( - >$ ++(' N

(64) (+(!. J. !"

(65)

(66)

(67)

(68) ( - #$'N +((!. J. #$

(69)

(70)

(71) $(' - >$( <'N $$0!. J. #!

(72) -$' &@ & +' (:<(!. J. % O3I!I..F 3 * 10!14 P I!I01C 3$H &: * M!C.4 P I!.KK / 33<'NMII4 Q I!CF04 P I!IKKM 3&'' (57(+' Q /!.44! R &@*(-$( 3? 4 S.!/= 'R T.!/. J. & !

(73)

(74) '&+( ++('(' $% /I=IIIN$(+= ' '(-$8(+ +- 6 '(-$#= '-$#( - 6(6= '-+( +$'$ ,(,(! '-+( .I*0ID &'' -

(75) 7 2' - -# (57(+= 5(& ' -+- 2' - ;(+= '-$#( #'(6= $$(- +-' '-#-' ' $(- '&+(= 6+(2- +(#-7(+! ?U '-+( $8' 0ID ?'' - -# (57(+ -

(76) 7 V' %N '-+( $' -2' -5$ - #' ('(-' '-# (57(+ $7 2'!. J.

(77) # !

(78)

(79) "

(80) ?'58-= %;%= -52- 5= &(-2'( +('(-!. J. # !

(81)

(82) '-+( '-$' % '(#-' (&(&'

(83) = ++(' $-' .I=IIIN$(+= <' $-' 1CI=IIIN$(+= '-+( #-+(' (-$' - '-# (57(+! ++(2- $-' CID ' ++(' 3'2 '( +- 5 T /I=IIIN$(+ (#-2'(+4 +- #-+(' (-$' - '-# (57(+ '-$#(! '' < - '' ,$2#(+ +(. J. #

(84) '

(85)

(86) ' ' $5'' 6' +'-+( $'$ ,(W C*01D $5'' 6' +'-+( $'$ ,(! X .IID $5'' 6' +- $'$ ,( '-!. J. "(

(87) - $''! ' 6(&' &-(' '( '-#- ' (:- - - +%- 0CII= 0MII! ' '(' +(#-7(+' ' &6(- $7 2' - $(

(88) + % 2 .I= +++($(- '(- '($+(2-= '(- 5(,$#(-(-= - & +(6 ( ' /1 ,' % ' M/ ,'= +- '( $-' ./ $5''!. K. "#$ %&'(' ) * +,' '- ".

(89) 2 17

(90). -+-- F. ,('(' +-(+' +(-' +-

(91) < +-&- +- ' +((' (-+'(2- % +- ' ' 6(&' '(= 7'' 5- #('' - ,@ 5$(! ++- ' 6' $(' % '6(+(-' '8- ' 6(&' +-((6'! '- +6' '&6(

(92) 7 Y-*

(93) %= +- 6+(2- '(5(+ + R= '

(94) (#-2'(+ % ( $(- +(&(! 62 +- '( # -R +- GCD SI=I. $' '( ' ''(+$- '(#-(5(+(6!. "#$ %&'(' ) * +,' '- ". G.

(95) ! " #$$%& $ &'( ) " * !$' ) $ ' $ + $ $ & "&$ ,,-./000. .I. "#$ %&'(' ) * +,' '- ".

(96) 2

(97) . 2

(98) . ->$ +'' -6' H

(99) -

(100) ' $' - (# .!.

(101)

(102) ! " #$$$ ('(&+(2- ';' 5 1/ 6-' 3FGD4 % .G $@' 30.D4 3(# /4! >$ +'' H -

(103) = - Z F.. "#$ %&'(' ) * +,' '- ". ...

(104) ! " #$$%& $ &'( ) " * !$' ) $ ' $ + $ $ & "&$ ,,-./000. # %& '(

(105) . !)#$$$ Z F. +(-' ' ' '& = ,$#&(-= ++('= <'= +-@ &'25(' % # '-$#( (#-2'(+= ' $'- - & .!. * + & &

(106) !)#$$$ :;< = >) "? $ " $ %@A 9 B 4) C B !' D 0M +(-' 3F.D4 - '-- &'' (#-2'(+ 3(# 04!. ! , - % &

(107) !)#$$$ Z F. +(-' ./. "#$ %&'(' ) * +,' '- ".

(108) 2

(109) . (#-' % '-$' (#-2'(+ ' $'- - & /!. * # ' . '/ & &

(110) !)#$$$ ; $*E #))( ( )$( $ '( )( '( #)( &( #))( @( $&( #)!>A .0 +(-' 3/.D4 - '-&- '-$#( (#-2'(+ 3(# 14 % .I +(-' 3.FD4 '-- '-$#( $8' .I +$ &@ & +' (:<( 3(# 14!. 0 , &

(111) !)#$$$ Z F. +(-' ./ +(-' 3/ID4 &- +- + R = // +(-' 30FD4 +- + R &@= % /M +(-' 311D4 +- + R (-$(! 35(# C4!. 1 ' '2 % &

(112) ! #$$$ Z F. +(-' (:2 '( +(#-7(+ '2 CI +(-' 3K.=GD4 '- 1M +(-' 3G1D4 +- '-+( $'$ ,(,(! 35(# F4! "#$ %&'(' ) * +,' '- ". .0.

(113) ! " #$$%& $ &'( ) " * !$' ) $ ' $ + $ $ & "&$ ,,-./000. 3 ,4 4 &

(114) !)#$$$ Z CI +(-'! CC +(-' 3GI!.D4 &- +- 5' +2-(+

(115) = C 3K!.D4 +- 5' -'5$+(2-= % . 3.!FD4 +- +('(' &8'(+! 35(# M4!. 5 &

(116) . ! #$$$ Z F. +(-'! ( +(-' 3..=1D4 +(&(- (#-2'(+ ?'58- 3+$ $-($ ' $''4! CG +(-' 3GF=MD4 +(&(- %;% (-(+( $(-! $% ' +(-' < +(&(- ?'58- (#-2'(+ +-(-- +(&(- %;%! - ' +(- 3.=MD4 +(&(2 (#-2'(+ ;+'(6$- ?'58-! - ' < +(&(- ?'58-= '(' (( $( 5 C!1 #N! - ' < +(&(%;%= '(' (( $( 5 .!F #N! &'5- 5 ' - $( .0!/ $'' 3-# 0*0F $''4 % '2 5 ' +$ $(- (-(+( ,' 5& .GGM= ( ' 5+,= <($(( #( +$ (-(+( $(-

(117) - 5' +2-(+ 5 ,%;%! %;% 5 +(&( ' +(-' - - $( 1C=/ $'' 3-# 1 *M/ $''4! - 6: < +- $(- (-(+( 3&'58- %;%4 ' +(-' #&- ('$(-( +- ++(( /I=IIIN$$0 $-'= ' (-(+(& $(- +- -52- 5! '= -52- 5 ' .M +(-' 3/M=KD4 $-' F $''! - $( 5 ' .F=0C $'' 3-# F Q 0G $''4! '(' $( (( (-5- 5 C!M

(118) N! - ' .M +(-' < '- -5-= .. ' 3F1=MD4 +(&(+-+$(-$- &(-2'( ('(- 3*4 (: <(-+ ' $'= 6 '&+8-= $-' ' $''! '(' $( * +(&( 5 /G!/ $#NN.I*.C ' $'! ' -+ +(-' < +(&(- -5- P *= .1. "#$ %&'(' ) * +,' '- ".

(119) 2

(120) . ,(+(- - $( M=G $'' 3-# 0 Q /. $''4!. ' FI +(-' < +(&(- % ' %;% ?'5- $-' ' $'' ' (#-2'(+= /M 311!/D4 #- &- '' $2#(+ $= /K +(-' 31C!GD4 - #- (+, '' % F +(-' 3G!K#D4 '2 #- - '' $2#(+ +(! ' ( +(-' < +(&(?'58- (#-2'(+

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

(122) ! " #$$%& $ &'( ) " * !$' ) $ ' $ + $ $ & "&$ ,,-./000. 35(# K4!. 6 7 '7 * &

(123) ! #$$$ Z F. +(-'! ' MI $'' (#-2'(+= .II D ' +(-' +- + R '8$'= % FC D ' +(-' +- + R &@ (-$( '8- 6(6'! ' .II $''= 1C D ' +(-' +- + R &@ (-$( >'8- 6(6'! - ' ($' 0I $'' -5$= '&6( ' '$@- - ' +(-' +- R % +- R &@ (-$( 35(# G4!. 7 '7 * ' '2 8- 9):; <= &

(124) ! #$$$ '7 ' % & Z F. +(-'! :;< 8B "?.). ' < '- -52- 5= ' MI $'' (#-2'(+= .II D ' +(-' '8- 6(6'= % - ' < - '-= 1C D '8 6(6! ' GI $''= CI D ' < '- (-52- 5 '8- 6(6' 6'' 0C D ' < - '- 35(# .I4!. .F. "#$ %&'(' ) * +,' '- ".

(125) 2

(126) . $ '7 :>& 4

(127) ! #$$$ B F' ' 0. &( /II.= ' F. +(-' '('= '2 1 3MD4 ' ' (:2

(128) #7-(+= % M 3..!1D4 +(-' - +-('

(129) #7-(+ +-- +$(&! 0I 31G!.D4 +(-' -- '(&(( - - -6 ( $(-= (-,(&( ('(-*<(-'!. ' F. +(-'= '2 . 3.=FD4 ,(: &-- $(-! ' $$- 5+, +( ' &@= ,&- 5+( .G +(-' 30.!.D4W ' +'' 5+($(- ' $'- - & 0!. * ! >

(130) !)#$$$. ' .G 5+('= .K +(-' 3G1!MD4 ,(+(- - +('(' &8'(+! ' +(-' 3.C!MD4 5+(- ;+'(6$- +- +('(' &8'(+ '(- +' -! $8' +('(' &8'(+= +, +(-' 31/!.D4 5+(- ''('= ' +(-' 3.C!MD4 '-# (-+&= ' +(-' 3.C!MD4 '' '*'-+$= - +(- 3C!/D4 $&'(' 9-' 5- % && $&$&('$ $- % - +(- 3C!/D4 $(- &( +(# <-(!. "#$ %&'(' ) * +,' '- ". .M.

(131) ! " #$$%& $ &'( ) " * !$' ) $ ' $ + $ $ & "&$ ,,-./000. .K. "#$ %&'(' ) * +,' '- ".

(132) 6. 6 +$(

(133) (( 2-(+ +8'(+ (- ' 5'' +2-(+= + % +('(' &8'(+! - $% ' +'' ' (#-'(+ - 5' +2-(+ 3M=K=G=.I4! - -' '(= GI!.D ' +(-' ' (#-'(+- - ' 5' +&- < 5( &(&(#5! ' '(#-' % '-$' '-+(2- +(-+(- +- ' < +- - (6'' &(++(-' 3/=C=M=K=G=..4! ' ,- - -(-#>- +(- '-$' +(-' +''('= ' +$ (--('= (('$= +$&(' ' $-! ' +(-' - '- (#-2'(+ #-' $-(5'+(-' '-# 3M=..4! ' M 3..!1D4 +(-' < &- +- #>- ( '-#= '2 ' 6(- <-( (#-2'(+= + ,+ '- < +' '-# $% ' +'' - 5 <-( '(- ('5-+(2- <(! - #- ,% - (# $(--+( - ,$&'= '(- +(2$&N

(134) @ Z .!0N. 3./=.04! - -' '(= ' +(2- 5 /!/N.! $( '-+(2- ' +(-' ' - 1C CC H' % ./ 0ID ' +(-' '- FI H' $%' 3.14! - -' '(= $( 5 1F!K H' % .M 3/M!KD4 +(-' -- $-' FI H' $8' (#-2'(+! - GCD ' +''

(135) ' 6(-+( '-+( $'$ ,(,(= $+ +(#-7(+ -5$ 3.C=.F4! -8('(' +(#-7(+ +8'(+= + (-(5(+8 +$'$ ,(,( - $8' GID ' +''= ' "#$ %&'(' ) * +,' '- ". .G.

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

(138) ! - (6'' '(' &(+'= ' , $' - 6-@ - ' 5-*5 $8' *+ '& ' 5-*5 '2= % < ' ,- # - (-+(-+( $8' '' ,$2#(+= '' +(#-7(+= -(+' '&6( $8' '! 3/K=/G=0I=0.4! # '(- #2 '' +(#-7(+ +$ .KD '- 5-*5 $8' *+ (: ' 30/4! - -' &@= .M!FD ' +(-' < +(&(- 5-*5 #- - '' +(#-7(+ 3' +$' % - +(4 + '8 - ' '#>- ' &(++(-' % +$-'! /I. "#$ %&'(' ) * +,' '- ".

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

(140) (#-2'(+= % < ' 1I $'' -5$= $-' /I D ' +(-' +- 5' + +('(' &8'(+ (#-2'(+ '8 6(6 6'' MCD ' +(-' +- 5' +2-(+ (#-2'(+! '&6( ' +(-' +- 5' +2-(+ (#-2'(+ ' 1ID ' .II $''! 6(& ($- - +- '&6( ' + R 30F4! - -' &@= - '+ 'R &@*(-$( - + ' 6-@' - +- '&6( - ' ($' 1I $'' -5$= % < +(-' +- 'R &@*(-$( % 'R (-- '&6( '$@-! ( ' $$-= 'R &@*(-$( '( + - - ' ($- - 6+(2- ' +(-'W - ' ' < ' MI $'' -(-#>- +(- +- '+ 'R ' 6(6 6'' ;($$- FID ' +(-' +- 'R &@*(-$(! (-+( -5< < +( '&6( # : ' '-

(141) 7 2' 3

(142) 4 #7-(+= += &( ' ($( (++(2- +(-' $8' @26-' +- -- +$(&= &&$- A+B '2 .CD ' ' +(-' +- -5$ 314! - '- &@= '2 1 3MD4 +(-'= 5(- '(= #- ' '$('

(143) #7-(+ +- &-' '' % M +(-' $8' 3..!1D4 +-&- +- -- +$(& % '&- 2;($'

(144) #7-(+= ' +( '2 .K!1D ' ' +(-' 6(- '(&((

(145) #7-(+! 1G!.D ' +(-' < - #- &- - '' +(#-7(+ + 5-*5= < '&- - 5' +2-(+= -'5$+(2- &8'(+ < - '-- <($(( +-6-+(-= -- '(&(( +(&( - -6 # < ' +$-:2 ' 7$(- '- (-6'(#+(2- ' (-,(&(' ('(-*<(-'!. "#$ %&'(' ) * +,' '- ". /..

(146) ! " #$$%& $ &'( ) " * !$' ) $ ' $ + $ $ & "&$ ,,-./000. //. "#$ %&'(' ) * +,' '- ".

(147) . . J. (#-2'(+

(148) + #-$- - 5' +2-(+!. J. - ' +(-' +-

(149) < &- +- #>- ( '-#= ' '-+( - ->$ -$ <'= 5-+(2- <( ' ' !. J. 8+(+$- ( ' +(-' +-

(150) 6(-+(- '-+( +$'$ ,(,( $7' +-6-+(-'!. J. '&6( ' $- ' +(-' +-

(151) (#-'(+' - 5' + - +('(' &8'(+!. J. '+ 'R &@ (-$( (#-2'(+

(152) '8 - +(2- - $% '&6( !. J. '&6( ' $% ' +(-' +-

(153) < +(&- -52- , - +$+(2- +- <' < - +(&-!. J.

(154) -' /I D ' +(-' (#-'(+' +-

(155) (-- ++' '- $7 2' #7-(+!. "#$ %&'(' ) * +,' '- ". /0.

(156) ! " #$$%& $ &'( ) " * !$' ) $ ' $ + $ $ & "&$ ,,-./000. /1. "#$ %&'(' ) * +,' '- ".

(157) 881

(158) 7

(159). 881

(160) 7

(161). Gaal Karl, Arber Daniel. Chronic Myelogenous Leukemia. October 2000, Volume 31, Number 10 Laboratory Medicine. Sawyers Charles. Chronic Myeloid Leukemia. April 29, 1999 volume 340, Number 17 The New England Journal of Medicine. Hill John, Meehan Kenneth. Chronic Myelogenous Leukemia curable with early diagnosis and treatment. September 1999, Vol 106, Number 3 Postgraduate Medicine. Goldman JM. Treatment of chronic myeloid leukaemia: some topical questions. 1997, Vol 10, Number 405, Baillieres Clin Haematology. Faderl Stefan, Talpaz Moshe, Estrov Zeev. Chronic Myelogenous Leukemia: Biology and Therapy. August 1999, Volume 131: 207-219, Annals of Internal Medicine. Melo Junia. Insights into the Molecular Pathophysiology of Chronic Myeloid Leukemia: Targets of Therapeutic Strategies?. American Society of Hematology (ASH) 1999. Cortes JE, Kantarjian H. Chronic Leukemias. In: Pazdur R, Coia LD, Hoskins EJ, et al. Cancer management: a multidisciplinary approach. 2d ed. Huntington, NY: Publisher Research Management, Inc, 1998; 306-15. Cortes JE, Talpaz M, Kantarjian H. Chronic Myelogenous Leukemia: a review. Am J Med 1996; 100(5):555-70. Cortes JE, Kantarjian HM, Giralt S, et al. Natural history and staging of chronic "#$ %&'(' ) * +,' '- ". /C.

(162) ! " #$$%& $ &'( ) " * !$' ) $ ' $ + $ $ & "&$ ,,-./000. myelogenous leukemia. Baillieres Clin Haematol 1997; 10(2):277-90. Hugues TP, Goldman JM, Chronic myeloid leukemia. In: Hoffman R, Benz EJ, Shattil SJ et al, eds. Hematology: basic principles and practice. 2d ed. New York: Churchill Livingstone, 1995:1142-59. Goldman J. Chronic myeloid leukaemia. BMJ (Clin Res Ed) 1997; 314:657-60. Brincker H. Population-based-age-and sex-specific incidence rates in the 4 main types of leukemia. Scan J Haematol. 1982;29:241-9. Baranovky A, Myers MH. Cancer incidence and survival in patients of age and older. CA Cancer J Clin, 1986;36:26-41. Faderl, Talpaz, Estrov, Kantarjian. Volume 341: 164-172, July 15, 1999, Number 3. The Biology of Chronic Myeloid Leukemia. The New England Journal of Medicine. Rowley JD: A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290,1973. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132:1497-1497. Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet, and monocyte/macrophage. Am J Med. 1977;63:125-130. Hehlmann R, Heimpel H, Hasford J et al. Randomized comparison of interferon alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 1994; 84:4064-77. Talpaz M, Mc Credie KB, Mavligit GM, Gutterman JU. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 1983;62:689-92. Ohnishi K, Ohno R, Tomonaga M et al. A randomized trial comparing interferon alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995; 86:906-16. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alpha 2ª as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330:820-5 Allan NC, Richards SM, Sheperd PC. UK Medical Research Council randomized, multicenter trial of interferon alpha for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet 1995;345:1392-7. The Chronic Myeloid Leukemia Trialists´Collaborative Group. Interferon alpha versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst 1997; 89:1616:20. Kantarjian HM, Smith TL, O´Brien S, Beran M, Pierce S, TalpazM. Prolongued survival in chronic myelogenous leukaemia after cytogenetic response to interferon alpha therapy. Ann Intern med 1995; 122:254-61. Kloke O, Niederle N, Qiu JY, Wandl U, Moritz T, Nagel-Hiemke M. Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukaemia. Br J Haematol 83:399,1993. /F. "#$ %&'(' ) * +,' '- ".

(163) 881

(164) 7

(165). Dexter TM, Chang J. New strategies for the treatment of chronic myeloid leukemia. Blood 84:673,1994. Gale RP, Hehlmann R, Mei-Jie Z, Hasford J, Goldman J. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. Blood, vol 91, Nº 5 (March 1), 1998: 1810-1819. Hagop M, Kantarjian, O´Brien S, Smith T. Treatment of Philadelphia Chromosome-Positive Early Chronic Phase Myelogenous Leukemia with daily doses of Interferon Alpha and low-dose cytarabine. Journal of Clinical Oncology, Vol 17,Nº1,1999:284-292. Kantarjian HM, Keating MJ, Estey EH, et al. Treatment of advanced stages of Philadelphia Chromosome-Positive chronic myelogenous leukemia with daily doses of Interferon Alpha and low-dose cytarabine. J Clin Oncol 1992;10:772-8. Patri S, Dascalesu C, Chomel JC et al. Monitoring and prognostic evaluation of sex-mismatched bone marrow transplantation by competitive PCR on Y chromosome sequences. Bone Marrow Transplant 1996;17:625-32. Guilot F, Guerci A, Maloisel F, et al. Follow up of 1047 patients with chronic myelogenous leukemia treated with interferon or interferon with cytarabine. Blood 1997;90:suppl 1, abstract 2299. Thaler J, Hilbe W, Apfelbeck U, et al. Interferon alpha 2 c and LD ara-c for the treatment of patients with CML: results of the Austrian multicenter phase II study. Leuk Res 1997;21:75-80. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JR. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann Inter Med 1991; 114:532-538. Tkachuk DC, Westbrook CA, Andreeff M, et al. Detection of bcr-abl fusion in chronic myelogenous leukemia by in situ hybridization. Science 1990;250:559-62. Muhlmann J, Thaler J, Hilbe W, et al. Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: a new strategy for remission assessment. Genes Chromosomes Cancer 1998;21:90-100. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA. Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F, Rozman C: Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 63:789,1984.. "#$ %&'(' ) * +,' '- ". /M.

(166) ! " #$$%& $ &'( ) " * !$' ) $ ' $ + $ $ & "&$ ,,-./000. /K. "#$ %&'(' ) * +,' '- ".

(167) 292 42 48. 292 42 48. '+# ; +$ - 5$ ? - (++(2- ,NN\\\!+%&'('!!N'('&(&N/II0N']N&N']!&. "#$ %&'(' ) * +,' '- ". /G.

(168)